Your browser doesn't support javascript.
loading
CD229 CAR T cells eliminate multiple myeloma and tumor propagating cells without fratricide.
Radhakrishnan, Sabarinath V; Luetkens, Tim; Scherer, Sandra D; Davis, Patricia; Vander Mause, Erica R; Olson, Michael L; Yousef, Sara; Panse, Jens; Abdiche, Yasmina; Li, K David; Miles, Rodney R; Matsui, William; Welm, Alana L; Atanackovic, Djordje.
Afiliação
  • Radhakrishnan SV; Multiple Myeloma Program & Cancer Immunotherapy, Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, 84112, USA.
  • Luetkens T; Multiple Myeloma Program & Cancer Immunotherapy, Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, 84112, USA. tim.luetkens@hci.utah.edu.
  • Scherer SD; Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, 84112, USA.
  • Davis P; Department of Pathology, University of Utah and ARUP Laboratories, Salt Lake City, UT, USA.
  • Vander Mause ER; Multiple Myeloma Program & Cancer Immunotherapy, Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, 84112, USA.
  • Olson ML; Multiple Myeloma Program & Cancer Immunotherapy, Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, 84112, USA.
  • Yousef S; Multiple Myeloma Program & Cancer Immunotherapy, Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, 84112, USA.
  • Panse J; Department of Oncology, Hematology, Hemostaseology, and Stem Cell Transplantation, University Hospital RWTH Aachen, Aachen, Germany.
  • Abdiche Y; Carterra Inc., Salt Lake City, UT, USA.
  • Li KD; Department of Pathology, University of Utah and ARUP Laboratories, Salt Lake City, UT, USA.
  • Miles RR; Department of Pathology, University of Utah and ARUP Laboratories, Salt Lake City, UT, USA.
  • Matsui W; Department of Oncology, The University of Texas at Austin, Austin, TX, USA.
  • Welm AL; Department of Oncological Sciences, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, 84112, USA.
  • Atanackovic D; Multiple Myeloma Program & Cancer Immunotherapy, Division of Hematology and Hematologic Malignancies, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, 84112, USA.
Nat Commun ; 11(1): 798, 2020 02 07.
Article em En | MEDLINE | ID: mdl-32034142
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores de Antígenos de Linfócitos T / Imunoterapia Adotiva / Família de Moléculas de Sinalização da Ativação Linfocitária / Mieloma Múltiplo Tipo de estudo: Prognostic_studies Limite: Animals / Humans / Male Idioma: En Ano de publicação: 2020 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Receptores de Antígenos de Linfócitos T / Imunoterapia Adotiva / Família de Moléculas de Sinalização da Ativação Linfocitária / Mieloma Múltiplo Tipo de estudo: Prognostic_studies Limite: Animals / Humans / Male Idioma: En Ano de publicação: 2020 Tipo de documento: Article